Physician profile
Lea Johnson
NPI 1407419187
$1,787.53
in general payments reported to CMS, 2019-2025
19 companies · $99.72 in 2025
The $99.72 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $92.49 · 2023: $626 · 2024: $970 · 2025: $99.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,695.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $397.93 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $251.01 | 2022-2024 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $201.72 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $146.48 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $137.37 | 2023-2025 | |
| Exact Sciences Corporation | $84.94 | 2024 | Cologuard Collection Kit |
| Harmony Biosciences LLC | $83.21 | 2024 | |
| Astellas Pharma US INC | $79.43 | 2024 | Veozah |
| Viiv Healthcare Company | $70.58 | 2024 | Apretude |
| Takeda Pharmaceuticals U.S.A., INC. | $68.20 | 2022-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.06 | 2023-2024 | Jardiance, Tradjenta |
| Amgen INC. | $48.15 | 2023-2024 | Otezla, Repatha |
| Organon LLC | $41.45 | 2023-2024 | Nexplanon |
| Axsome Therapeutics, INC. | $28.05 | 2023 | Auvelity |
| Dexcom, INC. | $24.30 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $21.11 | 2023 | Xarelto |
| Xeris Pharmaceuticals, INC. | $19.10 | 2022 | |
| Recor Medical INC | $14.76 | 2024 | Paradise Renal Denervation System |
| Azurity Pharmaceuticals, INC. | $14.68 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lea Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.